IBI306 + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia
Conditions
Heterozygous Familial Hypercholesterolemia
Trial Timeline
Dec 20, 2019 → Jun 30, 2021
NCT ID
NCT04179669About IBI306 + placebo
IBI306 + placebo is a phase 3 stage product being developed by Innovent Biologics for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04179669. Target conditions include Heterozygous Familial Hypercholesterolemia.
What happened to similar drugs?
1 of 14 similar drugs in Heterozygous Familial Hypercholesterolemia were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04709536 | Phase 3 | Completed |
| NCT04179669 | Phase 3 | Completed |
| NCT03815812 | Phase 2 | Completed |
| NCT03366688 | Phase 1 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 44 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 40 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 45 |
| Inclisiran | Novartis | Phase 3 | 44 |
| Inclisiran + Placebo | Novartis | Phase 3 | 40 |
| Fluvastatin | Novartis | Phase 3 | 40 |
| Inclisiran + Placebo | Novartis | Phase 3 | 47 |
| Evolocumab + Placebo | Amgen | Phase 3 | 40 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 40 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 29 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 40 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 40 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 40 |
| Praluent | Sanofi | Approved | 35 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 35 |
| lerodalcibep | Medpace | Phase 3 | 37 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 37 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 32 |